PD-1 or PD-L1 checkpoint inhibitors have routinely become part of the clinical approach for this type of cancer, which justifies the importance of researching PD-1/PD-L1 status in patients with advanced non-small cell lung cancer [23]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.